Compare Ecopetrol SA (EC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs TG Therapeutics Inc — how do they compare? Ecopetrol SA trades at $16 (market cap $30.44B), while TG Therapeutics Inc trades at $56.6 (market cap $8.64B). The key difference: Ecopetrol SA is far larger — about 3.5× TG Therapeutics Inc's market cap, and Ecopetrol SA pays a 4.06% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| EC | TGTX | |
|---|---|---|
Market Cap | $30.44B | $8.64B |
Sector | Energy | Health |
52-Week High | $16.58 | $59.06 |
52-Week Low | $8.29 | $26.39 |
Enterprise Value | $58.23B | $8.88B |
Dividend Yield | 4.06% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
